Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Hartford Investment Management Co.

Hartford Investment Management Co. decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.0% during the 3rd quarter, Holdings Channel.com reports. The fund owned 12,769 shares of the medical equipment provider’s stock after selling 394 shares during the period. Hartford Investment Management Co.’s holdings in Zimmer Biomet were worth $1,378,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Crewe Advisors LLC acquired a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $31,000. J.Safra Asset Management Corp grew its stake in Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 235 shares during the last quarter. Bangor Savings Bank acquired a new stake in Zimmer Biomet in the third quarter worth $31,000. Family Firm Inc. bought a new stake in Zimmer Biomet in the second quarter valued at $33,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of Zimmer Biomet during the second quarter valued at $43,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $102.35 on Friday. The stock’s fifty day simple moving average is $107.78 and its 200 day simple moving average is $111.76. The stock has a market capitalization of $21.06 billion, a price-to-earnings ratio of 22.15, a PEG ratio of 1.92 and a beta of 1.02. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The firm had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter last year, the business posted $1.82 EPS. Zimmer Biomet’s revenue was up 3.9% on a year-over-year basis. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.97 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Monday, September 30th. Zimmer Biomet’s dividend payout ratio is 20.78%.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. UBS Group cut their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research report on Thursday, August 8th. Raymond James cut their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. JPMorgan Chase & Co. decreased their price objective on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, September 16th. Morgan Stanley cut their target price on Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Finally, Canaccord Genuity Group decreased their price target on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $123.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.